Progenics Pharma (PGNX) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Progenics Pharma (PGNX) Misses Q4 EPS by 5c
March 16, 2015 8:02 AM EDT
TARRYTOWN, N.Y., March 16, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the fourth quarter and year-end 2014.
"We have reported significant progress in recent months, and begin 2015 with a pivotal trial underway for Azedra, two Phase 3-ready prostate cancer programs, and a strong balance sheet to support our high-value pipeline," stated Mark Baker, CEO of Progenics. "The data emerging from our PSMA ADC and 1404 programs are quite impressive, demonstrating the potential of these product candidates to change the way prostate cancer is diagnosed, monitored and treated.... More
March 16, 2015 8:00 AM EDT
TARRYTOWN, N.Y., March 16, 2015 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the fourth quarter and year-end 2014.
"We have reported significant progress in recent months, and begin 2015 with a pivotal trial underway for Azedra, two Phase 3-ready prostate cancer programs, and a strong balance sheet to support our high-value pipeline," stated Mark Baker, CEO of Progenics. "The data emerging from our PSMA ADC and 1404 programs are quite impressive, demonstrating the potential of these product candidates to change the way prostate cancer is diagnosed, monitored and treated.... More
